Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBio-4101 + Pembrolizumab in Advanced Solid Tumors
NCT05576077Phase 1Terminated
- Sponsor
- Turnstone Biologics
- Start
- Jan 2023
- Primary completion
- Feb 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of tidal-01 in breast cancer, colorectal adenocarcinoma, Uveal melanoma (UM) and 3 more (6 arms), sponsored by Turnstone Biologics. Primary endpoint: Safety and tolerability at 25 months. Started Jan 2023; status: terminated.
02
Drugs
tidal-01
03
Conditions
breast cancercolorectal adenocarcinomaUveal melanoma (UM)cutaneous melanoma (CM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05576077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576077.